Company news
Liminatus Pharma, Inc. (NASDAQ:LIMN) news
Every Liminatus Pharma, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T t...
August 24, 2026
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
August 18, 2026
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
August 13, 2026
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
June 3, 2026
Liminatus Pharma Announces Nasdaq Delisting Notification
May 21, 2026
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
March 17, 2026
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
February 17, 2026
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism a...
October 30, 2025
Liminatus Pharma, Inc. Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strat...
October 27, 2025
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypt...
July 28, 2025
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
July 25, 2025
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
July 24, 2025
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
July 22, 2025
Liminatus Pharma Announces Compliance with Nasdaq Filing Requirements
June 4, 2025
Iris Acquisition : Businesses announce Definitive Business Combination Agreement and plan to operate under Liminatus Pharma - Form 8-K
December 1, 2022
Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments
November 30, 2022
Tribe Capital Growth I : Announces Name Change to Iris Acquisition Corp and Other Management Changes - Form 8-K
July 27, 2022